Cowen was feeling pretty good about the oil services sector until it surveyed exploration & production firms and found that its original spending estimates were off. Way off. Like a Blaine Gabbert pass.
Agence France-Presse/Getty ImagesAs a result, the knives have come out. Cowen’s analysts downgraded six stocks–Baker Hughes (BHI), Cameron International (CAM), Nabors Industries (NBR), CGG (CGG), Superior Energy Services (SPN) and Helmerich & Payne (HP)–and cut their estimates on even more. Its analysts explain why:
Our Original E&P Spending Survey published today estimated just 4% growth globally in E&P spend in 2014. Given our estimates were based upon an 8% gain in 2014 and a similar increase in 2015, we are lowering our estimates for many of the stocks we cover.
As the market digests a slower growth outlook for 2014, we think consensus earnings estimates will come down. It will be difficult for the oil service and drilling stocks to perform well given this scenario. Thus, we are lowering our opinion on six of the stocks we cover.
Top China Stocks To Own For 2015: Redcliffe Resources Ltd (RCF)
Redcliffe Resources Limited, formerly Pacrim Energy Limited, is engaged in gold exploration. The Company own 100% interest in Redcliffe Gold Project. The Redcliffe Gold Project lies northeast of the mining town of Leonora, which is 230 kilometer north of Kalgoorlie in Western Australia. The Project covers approximately 45 kilometers of strike length of the Mertondale Shear Zone (MSZ) along with parallel and associated structures. The Golden Terrace South (GTS) deposit lies within a granted mining lease in the southern portion of the Redcliffe Gold Project. The 727 Prospect is located less than five kilometer south east of Golden Terrace. The Kelly Prospect lies along the Mertondale Shear Zone some three to four kilometer north of Golden Terrace South. Advisors' Opinion:- [By Tom Stoukas]
Teleperformance SA (RCF) climbed 2.9 percent to 35.10 euros. Societe Generale SA raised its recommendation on the French operator of call centers to buy from hold. The brokerage said the shares��recent decline provides a buying opportunity. The stock has fallen 14 percent since its high on July 18.
Best Oil Service Stocks To Buy For 2014: Suedzucker Mannheim Ochsenfurt AG (SZU)
Suedzucker Mannheim Ochsenfurt AG is a Germany-based company engaged in the processing of agricultural raw materials. The Company is organized, along with its subsidiaries, into four segments: the Sugar segment comprises sugar production and the agricultural division; the Special Products segment includes the activities of four divisions: BENEO, which produces and sells ingredients made from natural raw materials for food products and animal feed; the Freiberger Group is a producer of chilled and frozen pizzas, frozen pasta dishes and snacks; the PortionPack Europe group specializes in portion packs, and the starch division comprises starch companies in Hungary and Romania, bio-ethanol production in Austria and Hungary, as well as starch production facilities in Austria; the CropEnergies segment includes the bio-ethanol activities of the Company in Germany, Belgium and France, and the Fruit segment comprises the fruit juice preparations and fruit juice concentrates divisions. Advisors' Opinion:- [By Jonathan Morgan]
Volkswagen AG (VOW), Europe�� biggest automaker, climbed 3.7 percent as data showed European car sales increased for the first time in 19 months in April. Suedzucker AG (SZU) dropped to an eight-month low as J&E Davy Holdings Ltd. downgraded the shares.
Best Oil Service Stocks To Buy For 2014: Kate Spade & Co (KATE)
Kate Spade & Co, formerly Fifth & Pacific Companies Inc, incorporated in January 1976, designs and markets a portfolio of retail-based, premium brands, including JUICY COUTURE, KATE SPADE and LUCKY BRAND. The Company also has a private brand jewelry design and development division, which markets brands through department stores and serves J.C. Penney Corporation, Inc. (JCPenney), through exclusive supplier agreements for the LIZ CLAIBORNE and MONET jewelry lines and Kohl's Corporation (Kohl's) through an exclusive supplier agreement for DANA BUCHMAN jewelry. It also has licenses for the LIZ CLAIBORNE NEW YORK brand, available at QVC and LIZWEAR, which is distributed through the club store channel. It maintains an 18.75% stake in MEXX, a European and Canadian apparel and accessories retail-based brand. As of December 31, 2011, the Company operated a total of 307 specialty retail stores under various Company trademarks, consisting of 285 retail stores within the United States and 22 retail stores outside of the United States (primarily in Europe and Canada). The Company operates in four segments: JUICY COUTURE segment, KATE SPADE segment, LUCKY BRAND segment, and Adelington Design Group & Other segment. In August 2013, Granite Real Estate Investment Trust closed its acquisition of a 600,000 square foot logistics-distribution facility in West Chester (Cincinnati), Ohio from the Company. In February 2014, the Company completed the sale of Lucky Brand Dungarees Inc.
JUICY COUTURE segment consists of the specialty retail, outlet, concession, wholesale apparel, wholesale non-apparel (including accessories, jewelry and handbags), e-commerce and licensing operations of its JUICY COUTURE brand. KATE SPADE segment consists of the specialty retail, outlet, wholesale apparel, wholesale non-apparel, e-commerce and licensing operations of its KATE SPADE and JACK SPADE brands. LUCKY BRAND segment consists of the specialty retail, outlet, wholesale apparel, wholesale non-apparel, e-commerce and licensing ! operations of its LUCKY BRAND. Adelington Design Group & Other segment consists of exclusive arrangements to supply jewelry for the DANA BUCHMAN, LIZ CLAIBORNE and MONET brands; the wholesale non-apparel operations of the TRIFARI brand and licensed KENSIE brand; the wholesale apparel and wholesale non-apparel operations of the licensed LIZWEAR brand and other brands, and the licensed LIZ CLAIBORNE NEW YORK brand.
JUICY COUTURE
The Company�� JUICY COUTURE brand offers luxurious, casual and fun women's and girl's apparel, as well as accessories and jewelry under various JUICY COUTURE trademarks. JUICY COUTURE products are sold through wholly owned specialty retail and outlet stores, select upscale specialty retail stores and department stores throughout the United States, through a network of distributors and owned and licensed retail stores in Asia, Canada, Europe, South America and the Middle East, as well as through its JUICY COUTURE e-commerce Website. In addition, JUICY COUTURE has existing licensing agreements for fragrances, footwear, optics, watches, swimwear, electronics cases and baby products.
KATE SPADE
The Company�� KATE SPADE brand offers fashion products (accessories, apparel and jewelry) for women and men under the KATE SPADE and JACK SPADE respectively. These products are sold primarily in the United States through wholly owned specialty retail and outlet stores, select specialty retail and upscale department stores, its operations in Brazil and the United Kingdom and through its KATE SPADE e-commerce Website, as well as through joint ventures in Japan and China and through a network of distributors in Asia. KATE SPADE's product line includes handbags, small leather goods, fashion accessories, jewelry and apparel. In addition, KATE SPADE has licensing agreements for footwear, optics, fragrances, tabletop products, legwear, electronics cases, bedding and stationery. JACK SPADE products include briefcases, travel bags, small leather go! ods and a! pparel.
LUCKY BRAND
The Company�� LUCKY BRAND offers an expanded assortment of men's and women's denim, woven and knit tops, dresses and sweaters, graphic tees, as well as accessories and jewelry, under various LUCKY BRAND. LUCKY BRAND products are available for sale at wholly owned specialty retail and outlet stores in the United States and Canada, select department and specialty stores and through the LUCKY BRAND e-commerce Website. LUCKY BRAND also has licensing agreements for fragrances, footwear, swimwear, eyewear and electronic cases.
Adelington Design Group & Other
The operations within the Company Adelington Design Group & Other segment consist of exclusive supplier arrangements to provide JCPenney with LIZ CLAIBORNE and MONET branded jewelry and Kohl's with DANA BUCHMAN-branded jewelry for two years; a license to produce and sell jewelry under the KENSIE brand name; a royalty free license for the LIZ CLAIBORNE NEW YORK brand; LIZWEAR, women's apparel available through the club store channel, and TRIFARI, a signature jewelry brand for women sold in mid-tier department stores.
The Company competes with Marc by Marc Jacobs, JCrew, Michael Kors, Pink, Coach, Diane von Furstenberg, Diesel, Guess, True Religion, 7 for all Mankind, Abercrombie & Fitch, and Tory Burch.
Advisors' Opinion:- [By WWW.DAILYFINANCE.COM]
Cindy Ord/Getty Images It may be back-to-school shopping season, but this doesn't mean that moms -- or other well-to-do fashionistas -- can't snap up a seasonal bargain. There may never be a better time to buy designer totes, satchels or shoulder bags. This is the time of year when Coach (COH), Michael Kors (KORS) and Kate Spade (KATE) usually discount some of their dated product lines ahead of new fall arrivals. But the markdowns may be even juicier this summer. Gross margins are contracting, and inventory is starting to build up. This is bad news for handbag makers and investors, but it should be good news for folks looking to buy a luxury purse. Let's Fly Coach Coach is the largest of the three luxury handbag makers, but that's about to change. After yielding market share to Michael Kors and to a lesser extent Kate Spade in recent years, analysts see Michael Kors overtaking Coach this upcoming holiday shopping season. Coach isn't doing very well. Sales and adjusted earnings are fell 7 percent and 35 percent, respectively, in its latest quarter. However, investors were braced for an even sloppier showing. Strong international sales, particularly in China, helped offset some but clearly not all of the domestic shortfalls (Coach suffered a 16 percent decline in North American sales). Coach was the only one of the three publicly traded luxury handbag makers to see its stock climb the trading day after announcing results. The other two are growing, but there are problematic signs for investors across all three players. Calling a Spade a Spade Kate Spade is the smallest of the three, and it was the last of the three to report. After unloading its Juicy Couture apparel and Lucky Brand premium denim lines, Kate Spade has been able to focus on its booming premium handbag and accessories business. Kate Spade's sales soared 49 percent in its latest quarter, and it was able to turn a year-ago deficit into an adjusted profit this time around. The stock still too
- [By Andrew Marder]
After announcing a 30.4% increase in comparable sales, Kate Spade (NYSE: KATE ) shot up in early morning trading on Tuesday this week. But by noon, the stock had fallen close to 20%, erasing the stock's 2014 gains. What sort of problem lurked below the surface that caused the decline? Promotions. Kate said that its Kate Spade Saturday brand, which had been a highflier, took a hit on overstocked merchandise, and helped push gross margins down 3 percentage points from 2013's second quarter.
Best Oil Service Stocks To Buy For 2014: Genomic Health Inc (GHDX)
Genomic Health, Inc. (Genomic Health), incorporated in August 2000, is a molecular diagnostics company focused on the global development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions. Its Oncotype DX platform utilizes quantitative genomic analysis known as reverse transcription polymerase chain reaction (RT-PCR), in standard tumor pathology specimens to provide tumor-specific information, or the oncotype of a tumor. As of February 2012, Oncotype DX was evaluated in invasive breast cancer in 13 clinical studies involving more than 4,000 breast cancer patients worldwide. Genomic Health offers its Oncotype DX tests as a clinical service, where it analyzes the expression levels of genes in tumor tissue samples and provide physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score, for invasive breast cancer and colon cancer and a DCIS Score for DCIS. Its Oncotype DX breast cancer test analyzes the expression levels of 21 genes and Oncotype DX colon cancer test analyzes the expression levels of 12 genes. In March 2012, the Company established a wholly owned subsidiary, InVitae Corporation.
Oncotype DX Platform
The Company�� Oncotype DX platform uses its RT-PCR approach to improve cancer treatment decisions. Its diagnostic approach correlates gene expression to clinical outcomes and provides an individualized analysis of each patient's tumor. The Company has built a diagnostic infrastructure that allows it to move from research into development through to processing actual patient samples in its clinical reference laboratory. The Company offers Oncotype DX tests as clinical laboratory services. Its technology allows the Company to analyze tumor tissue samples in its clinical reference laboratory and provide physicians with genomic information specific to the patient'! s tumor. It analyzes tissues that are handled, processed and stored under routine clinical pathology laboratory practices.
Oncotype DX Breast Cancer Test
To develop its Oncotype DX breast cancer test, the Company evaluated 250 genes in three independent clinical studies, which identified a 21-gene panel whose composite gene expression profile can be represented by a breast cancer Recurrence Score. The Company conducted studies of its Oncotype DX breast cancer test with clinical samples from postmenopausal women with invasive breast cancer who were treated with aromatase inhibitors. In March 2010, the Journal of Clinical Oncology published results from a European study using its test to analyze tumor samples from over 1,200 patients in the ATAC (Arimedix, Tamoxifen, Alone or in Combination) trial, which established the use of aromatase inhibitors for adjuvant treatment of postmenopausal women with hormone receptor-positive breast cancer. The study demonstrated that, along with other standard measures, such as tumor size, its Oncotype DX breast cancer test contributes independently to provide a more complete picture of prognosis for N- and N+ patients treated with aromatase inhibitors.
In December 2011, the Company presented positive results from the ECOG E5194 DCIS clinical validation study at SABCS. The study met its primary endpoint by demonstrating that a pre-specified Oncotype DX DCIS Score can predict the risk of local recurrence, defined as either the development of a new invasive breast cancer or the recurrence of DCIS in the same breast. In December 2011, the Company made Oncotype DX available for patients with ductal carcinoma in situ (DCIS), of the breast, a pre-invasive form of breast cancer. The launch of Oncotype DX for DCIS patients was based on positive results presented from a clinical validation study of Oncotype DX breast cancer test in patients with DCIS, conducted by the Eastern Cooperative Oncology Group (ECOG), a clinical trials cooperative! group su! pported by the National Cancer Institute.
Oncotype DX Colon Cancer Test
The Company developed its gene panel by identifying 761 cancer-related genes through review of existing research literature and computer analysis of genomic databases. The 761 candidate genes were also examined to determine whether they would be useful beyond other key variables including tumor stage, tumor grade, lymph nodes examined and MMR/MSI. It selected a final set of 12 genes, which were then independently evaluated in a validation study of over 1,400 stage II colon cancer patients from the Quick and Simple and Reliable (QUASAR), randomized study of adjuvant chemotherapy in the United Kingdom. This international, multi-center randomized trial examined the recurrence risk and the benefit associated with 5-fluorouracil/leucovorin, or 5FU/LV, adjuvant chemotherapy. Gene expression was quantified by RT-PCR from manually microdissected FPE primary colon cancer tissue, and recurrence-free interval, disease-free survival and overall survival were analyzed. In January 2012, the Company presented positive results of the first clinical decision making study of the Oncotype DX colon cancer test that shows that Recurrence Score result has a significant impact on treatment recommendations for stage II colon cancer patients.
The Company competes with General Electric Company, Hologic, Inc., Novartis AG, Myriad Genetics, Inc., Qiagen N.V., Response Genetics, Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Roche Holding, Ltd, Siemens AG and Johnson & Johnson.
Advisors' Opinion:- [By John Udovich]
On Tuesday, small cap cancer diagnostic stock Myriad Genetics, Inc (NASDAQ: MYGN) jumped 11.42% in one day, meaning its worth taking a closer look at the stock along with the performance of small cap cancer diagnostic stocks like Rosetta Genomics Ltd (NASDAQ: ROSG) and�Genomic Health, Inc (NASDAQ: GHDX) plus mid cap diagnostic stock Quest Diagnostics Inc (NYSE: DGX). I should mention that we have had�Myriad Genetics in our SmallCap Network Elite Opportunity (SCN EO) portfolio since February 5th and we are already up 18.50%���a nice return in just two weeks time.
- [By Jon C. Ogg]
Genomic Health Inc. (NASDAQ: GHDX) was downgraded to Underperform from an already cautious Neutral and the price target was cut to $33 from $36 by Bank of America�Merrill Lynch.
- [By John Udovich]
Small cap genomics stocks Rosetta Genomics Ltd (NASDAQ: ROSG), Genomic Health, Inc (NASDAQ: GHDX) and CollabRx Inc (NASDAQ: CLRX) are at the forefront of genomics testing�or research. I should mention that Wikipedia defines genomics�as a�discipline in genetics that applies recombinant DNA, DNA sequencing methods and bioinformatics to sequence, assemble and analyze the function and structure of genomes (the complete set of DNA within a single cell of an organism). A 2013 Booz Allen Hamilton report on the sector noted that in�2011, the US genetic and genomic clinical testing market size was estimated to be $5.9 billion while the�number of available tests has grown substantially from 1,680 just 4 years ago to 2,886 in 2012.
Best Oil Service Stocks To Buy For 2014: General Growth Properties Inc (GGC)
General Growth Properties, Inc. (GGP), incorporated on July 1, 2010, is a real estate investment trust (REIT). The Company owns or with joint venture partners 144 regional malls (126 domestic and 18 in Brazil) consists of approximately 135 million square feet. The Company is engaged in ownership, operation, management and selective re-development of its Consolidated Properties and Unconsolidated Properties, which are primarily regional malls.
As of December 31, 2012, the Company's segment was consists of 126 regional malls in the United States and 18 malls in Brazil, eight strip centers totaling 1.6 million square feet, primarily in the Western region of the United States, as well as seven stand-alone office buildings totaling 0.9 million square feet, concentrated in Columbia, Maryland. The Company also own interests in regional malls in Brazil.
Advisors' Opinion:- [By Holly LaFon]
His largest new buys in the first quarter are: Penn Virginia Group Holdings LP (PVG), Wynn Resorts Ltd. (WYNN), Methanex Corp. (MEOH), Solutia Inc. (SOA) and Georgia Gulf (GGC). Of his top eight stocks, five are from the chemicals industry.
Best Oil Service Stocks To Buy For 2014: Great Northern Iron Ore Properties (GNI)
Great Northern Iron Ore Properties, a conventional nonvoting trust, owns and leases mineral and non-mineral properties on the Mesabi Iron Range in northeastern Minnesota. It owns mineral interests on the Mesabi Iron Range formation that represent 12,033 acres, including approximately 9,895 acres are under lease and 2,138 acres are unleased. The company was founded in 1906 and is based in Saint Paul, Minnesota.
Advisors' Opinion:- [By Aaron Levitt]
PrairieSky won�� actually be drilling for oil or natural gas on its properties, nor will it be transporting it through pipelines. That’s because a�royalty trust is an entity�that own the production rights on oil wells, natural gas fields or, as in the case of Great Northern Iron Ore Properties (GNI),�iron ore mines.
No comments:
Post a Comment